{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:02:45Z","timestamp":1792558965431,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373044"],"award-info":[{"award-number":["82373044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022LSW001"],"award-info":[{"award-number":["ZR2022LSW001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218203","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:29:44Z","timestamp":1764779384000},"page":"218203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions"],"prefix":"10.1016","volume":"639","author":[{"given":"Xue","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuankun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8900","authenticated-orcid":false,"given":"Yintao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218203_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non\u2010small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2025.218203_bib2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer\u2014epidemiology, pathogenesis, treatment and molecular aspect (Review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218203_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218203_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"Non\u2013Small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2025.218203_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic Non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced Non\u2013small-cell lung cancer","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet. Lond. Engl."},{"key":"10.1016\/j.canlet.2025.218203_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib10","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous Non\u2013small-cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib11","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-Year fixed-duration nivolumab in previously treated advanced Non\u2013small-cell lung cancer: checkmate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non\u2013small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with Non\u2013small-cell lung cancer and programmed death Ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"De Castro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib14","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic Non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.218203_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJMra1911109","article-title":"Tolerance in the age of immunotherapy","volume":"383","author":"Bluestone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib19","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218203_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2025.218203_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218203_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8544","article-title":"Timing of immunotherapy in stage IV non-small cell lung cancer","volume":"42","author":"Komiya","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.14740\/wjon1924","article-title":"Prognostic implications of timing of immunotherapy in stage IV non-small cell lung cancer","volume":"15","author":"Vazquez-Urrutia","year":"2024","journal-title":"World J. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009627","article-title":"Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC","volume":"12","author":"Huo","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib28","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218203_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105607","article-title":"Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study","volume":"113","author":"Huang","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2025.218203_bib30","article-title":"Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: a retrospective multicenter study","volume":"228","author":"Tsukaguchi","year":"2025","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.canlet.2025.218203_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218203_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imm.13897","article-title":"Chronological effects of immune checkpoint inhibitors in non-small cell lung cancer","volume":"174","author":"Guo","year":"2025","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2025.218203_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218203_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jtho.2023.10.004","article-title":"Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib36","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","article-title":"Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade","volume":"43","author":"Tsai","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101788","article-title":"Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies","volume":"38","author":"Vryza","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216365","article-title":"Circulating tumor DNA as liquid biopsy in lung cancer: biological characteristics and clinical integration","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218203_bib44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/biomedicines11020508","article-title":"Circulating biomarkers for prediction of immunotherapy response in NSCLC","volume":"11","author":"Goh","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2025.218203_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer","volume":"582","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218203_bib47","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ijc.32145","article-title":"Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer","volume":"145","author":"Liu","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005509","article-title":"Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment","volume":"11","author":"Kim","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib49","article-title":"Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer","volume":"11","author":"Marcos","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib51","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218203_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218203_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218203_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006234","article-title":"Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib57","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218203_bib58","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1038\/s41467-025-58553-4","article-title":"Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancer","volume":"16","author":"Preet","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218203_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00262-024-03660-2","article-title":"Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China","volume":"73","author":"Yan","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.canlet.2025.218203_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002262","article-title":"Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy","volume":"9","author":"Ferdinandus","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib62","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib63","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41571-025-01029-7","article-title":"Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer","volume":"22","author":"Tang","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib65","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-Escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib66","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2025.218203_bib68","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.3390\/curroncol31060258","article-title":"A review of immunotherapy in non-small-cell lung cancer","volume":"31","author":"Capella","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced Non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib70","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1\u2013Positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib71","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cllc.2023.06.005","article-title":"Continuous vs. fixed 2-year duration immune checkpoint inhibitor treatment of patients with non-small cell lung cancer: a single institution database analysis","volume":"24","author":"Kobayashi","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib74","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib75","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and Nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib76","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib77","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous Non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib79","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous Non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib80","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet. Lond. Engl."},{"key":"10.1016\/j.canlet.2025.218203_bib81","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic Non\u2013small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib82","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib83","unstructured":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). Meeting Abstract: 2025 ASCO Annual Meeting I."},{"key":"10.1016\/j.canlet.2025.218203_bib84","unstructured":"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.Meeting Abstract: 2025 ASCO Annual Meeting I."},{"key":"10.1016\/j.canlet.2025.218203_bib85","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","article-title":"CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors","volume":"5","author":"Liu","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.canlet.2025.218203_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-Engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2025.218203_bib87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib89","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet. Lond. Engl."},{"key":"10.1016\/j.canlet.2025.218203_bib90","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib91","article-title":"Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti-programmed cell death protein 1\/Programmed death-ligand 1-Based therapy: final results from a phase 2 study","volume":"5","author":"Krebs","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.canlet.2025.218203_bib92","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib93","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: Five-Year overall survival outcomes from the phase 3 POSEIDON trial","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib96","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of Anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib97","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib98","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-Positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Yang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib99","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8502","article-title":"CAMPASS: benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)\u2014A randomized, single-blind, multicenter phase 3 study","volume":"43","author":"Han","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib102","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.21037\/tlcr-22-644","article-title":"International consensus on radiotherapy in metastatic non-small cell lung cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2024.04.001","article-title":"Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): diagnostic and therapeutic challenges of a different disease","volume":"51","author":"Giulia","year":"2024","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib104","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib105","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib106","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib107","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012Resistant, EGFR-Mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-2600(18)30500-9","article-title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","volume":"7","author":"Leighl","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.canlet.2025.218203_bib110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2025.218203_bib111","article-title":"Advances in the treatment of KRASG12C mutant non-small cell lung cancer","volume":"131","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib112","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small cell lung cancer: results of an open-label, multicenter, phase 1B study","volume":"15","author":"Felip","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib113","unstructured":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. Meeting Abstract: 2025 ASCO Annual Meeting I."},{"key":"10.1016\/j.canlet.2025.218203_bib114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cncr.33984","volume":"128","author":"Kim","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib115","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00262-021-03114-z","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2025.218203_bib116","first-page":"120","article-title":"Reassessing patterns of response to immunotherapy with PET: from morphology to metabolism","volume":"41","author":"Costa","year":"2021","journal-title":"Radiogr. Rev. Publ. Radiol. Soc. N Am. Inc"},{"key":"10.1016\/j.canlet.2025.218203_bib117","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib118","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","article-title":"Early ctDNA and survival in metastatic colorectal cancer treated with immune checkpoint inhibitors: a secondary analysis of the SAMCO-PRODIGE 54 randomized clinical trial","volume":"11","author":"Ta\u00efeb","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib121","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218203_bib122","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib123","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib124","article-title":"Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218203_bib125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.218203_bib126","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","article-title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","volume":"2","author":"Li","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.canlet.2025.218203_bib127","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2025.218203_bib128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00262-021-03115-y","article-title":"The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2025.218203_bib129","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2025.218203_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216998","article-title":"Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: a nationwide retrospective cohort study","volume":"596","author":"Kim","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218203_bib131","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study","volume":"119","author":"Fujimoto","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.218203_bib132","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.3390\/curroncol31060258","article-title":"A review of immunotherapy in non-small-cell lung cancer","volume":"31","author":"Capella","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib133","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib134","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024: featured updates to the NCCN guidelines","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2025.218203_bib135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of Re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.218203_bib136","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib137","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11864-022-00995-9","article-title":"Immune checkpoint inhibitor rechallenge after prior immune toxicity","volume":"23","author":"Bylsma","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib138","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.21037\/tlcr-22-360","article-title":"Efficacy, prognosis and safety analysis of anti-PD-1\/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study","volume":"11","author":"Yang","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103434","article-title":"Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2025.218203_bib140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.canlet.2025.218203_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1471409","article-title":"Cross-omics strategies and personalised options for lung cancer immunotherapy","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218203_bib142","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218203_bib143","article-title":"Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218203_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314978","article-title":"Multi-omics immune interaction networks in lung cancer tumorigenesis, proliferation, and survival","volume":"23","author":"Ye","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218203_bib145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218203_bib146","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.canlet.2025.218203_bib147","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218203_bib148","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.canlet.2025.218203_bib149","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/17407745231220661","article-title":"Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies","volume":"21","author":"Zang","year":"2024","journal-title":"Clin. Trials Lond Engl."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500775X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500775X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:52Z","timestamp":1792096912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352500775X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":149,"alternative-id":["S030438352500775X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218203","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218203"}}